BG
COGT icon

Bellevue Group’s Cogent Biosciences COGT Stock Holding History

Bellevue Group’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$188K Buy
+4,870
New +$170K ﹤0.01% 127

Other funds holding COGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Bellevue Group's COGT Position: Q2 2026 in Review

Bellevue Group opened a new position in Cogent Biosciences (COGT) in Q2 2026: 4,870 shares worth $188K. The stake represents ﹤0.01% of the portfolio and ranks #127 among its holdings.

267 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Bellevue Group held 4,870 shares of Cogent Biosciences worth $188K as of Q2 2026.
  • Cogent Biosciences was a new Bellevue Group position in Q2 2026.
  • Cogent Biosciences made up ﹤0.01% of Bellevue Group's portfolio in Q2 2026, its #127 holding.
  • 267 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.